



Gene Therapy Used in Cancer Treatment

Guest Editor:

Dr. Vincenzo Cerullo

Laboratory of
Immunovirotherapy, Drug
Research Program, Faculty of
Pharmacy, University of Helsinki,
00014 Helsinki, Finland

Deadline for manuscript
submissions:

closed (15 March 2014)

Message from the Guest Editor

Dear Colleagues,

This special issue "Gene Therapy for Cancer Treatment" will be mainly focused on the different aspects of cancer gene therapy, gene immunotherapy and immunovirotherapy.

For long time the term "Cancer Gene Therapy" has been mostly referred to oncolytic viruses or viral vector expressing anti-tumor molecules, leaving aside immunotherapy approaches. Nowadays several studies have highlighted the capacity of viral and non-viral approaches to "turn-on" the immune system and the use of this feature to further potentiate the efficacy of the treatment.

More specifically, in this issue papers can be focused on viral and non-viral approaches to cancer therapy, their use as immunotherapy platforms, their modification to increase the safety and/or immunogenicity. Both preclinical and clinical studies will be considered.

Dr. Vincenzo Cerullo

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)